Aurobindo Pharma Ltd.

Aurobindo Pharma’s arm gets ANVISA’s nod for biosimilars manufacturing facility in Hyderabad

The approval strengthens the company's capability to supply biosimilar products to the Brazilian and broader Latin American markets

Aurobindo Pharma’s arm incorporates subsidiary in Indonesia

The object of incorporation of this wholly owned stepdown subsidiary is to undertake manufacturing operations in Indonesia

Aurobindo Pharma gains as its arm completes acquisition of Lannett Company

Lannett has become a wholly owned subsidiary of Aurobindo Pharma USA Inc

Aurobindo Pharma’s arm completes acquisition of Lannett Company

Lannett has become a wholly owned subsidiary of Aurobindo Pharma USA Inc

USFDA completes inspection at Aurobindo Pharma’s arm’s Andhra Pradesh facility

The inspection concluded with 2 observations and will be responded to within the stipulated time

Aurobindo Pharma moves up as its arm gets US FTC’s approval to acquire Lannett

The transaction, valued at $250 million on a cash-free, debt-free basis and inclusive of normalized working capital, is expected to close before the end of June 2026

Aurobindo Pharma informs about press release

Aurobindo Pharma’s arm gets US FTC’s approval to acquire Lannett

The transaction, valued at $250 million on a cash-free, debt-free basis and inclusive of normalized working capital, is expected to close before the end of June 2026

Aurobindo Pharma jumps as its arm gets US FTC’s nod for acquiring 100% of membership interest in Lannett

This acquisition strengthens its ability to serve the U.S. generics space and provides strategic diversification into a specialized, high-value therapeutic category

Aurobindo Pharma’s arm gets US FTC’s nod for acquiring 100% of membership interest in Lannett

This acquisition strengthens its ability to serve the U.S. generics space and provides strategic diversification into a specialized, high-value therapeutic category

Aurobindo Pharma informs about disclosure

Aurobindo Pharma gains on getting USFDA’s final nod for Tofacitinib Tablets

The product will be manufactured at APL Healthcare Unit IV, a wholly owned subsidiary of the company and will be launched immediately

Aurobindo Pharma gets USFDA’s final nod for Tofacitinib Tablets

The product will be manufactured at APL Healthcare Unit IV, a wholly owned subsidiary of the company and will be launched immediately

Aurobindo Pharma gains on inaugurating biologics contract manufacturing facility ‘TheraNym’

The facility is intended to support MSD supply chain, both domestic and export markets, subject to applicable approvals and customer requirements

Aurobindo Pharma inaugurates biologics contract manufacturing facility ‘TheraNym’

The facility is intended to support MSD supply chain, both domestic and export markets, subject to applicable approvals and customer requirements